Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.4.4 (
kinesin
)
5,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently,
kinesin
motor proteins have been focused on as targets for cancer therapy. Kinesins are microtubule-based motor proteins that mediate diverse functions within the cell, including the transport of vesicles, organelles, chromosomes and protein complexes, as well as the movement of microtubules. In the current study, the expression of
kinesin family member 18A
(
KIF18A
), a member of
kinesin
superfamily, was investigated in breast cancer using immunohistochemistry, and its effect on breast cancer prognosis was examined.
KIF18A
expression level was significantly associated with lymph node metastasis (P=0.047). In patients with high levels of
KIF18A
expression, survival was significantly poorer compared to patients with low levels of
KIF18A
expression (disease-free survival, P=0.030). Multivariate analysis revealed that venous invasion (hazard ratio, 9.22; 95% confidence interval, 3.90-23.66; P<0.001) and
KIF18A
expression (hazard ratio, 3.20; 95% confidence interval, 1.34-6.09; P=0.010) were independent predictive factors for lymph node metastasis.
KIF18A
may be a useful predictive marker for lymph node metastasis in breast cancer, which could facilitate curative adjuvant treatment.
...
PMID:Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer. 2758 39
The influenza virus is one of the major public health threats. However, the development of efficient vaccines and therapeutic drugs to combat this virus is greatly limited by its frequent genetic mutations. Because of this, targeting the host factors required for influenza virus replication may be a more effective strategy for inhibiting a broader spectrum of variants. Here, we demonstrated that inhibition of a motor protein
kinesin family member 18A
(
KIF18A
) suppresses the replication of the influenza A virus (IAV). The expression of
KIF18A
in host cells was increased following IAV infection. Intriguingly, treatment with the selective and ATP-competitive mitotic
kinesin
KIF18A
inhibitor BTB-1 substantially decreased the expression of viral RNAs and proteins, and the production of infectious viral particles, while overexpression of
KIF18A
enhanced the replication of IAV. Importantly, BTB-1 treatment attenuated the activation of AKT, p38 MAPK, SAPK and Ran-binding protein 3 (RanBP3), which led to the prevention of the nuclear export of viral ribonucleoprotein complexes. Notably, administration of BTB-1 greatly improved the viability of IAV-infected mice. Collectively, our results unveiled a beneficial role of
KIF18A
in IAV replication, and thus,
KIF18A
could be a potential therapeutic target for the control of IAV infection.
...
PMID:Selective and ATP-competitive kinesin KIF18A inhibitor suppresses the replication of influenza A virus. 3225 33